Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q96HP0
UPID:
DOCK6_HUMAN
Alternative names:
-
Alternative UPACC:
Q96HP0; A6H8X5; Q7Z7P4; Q9P2F2
Background:
Dedicator of cytokinesis protein 6 plays a pivotal role in cellular processes by acting as a guanine nucleotide exchange factor for CDC42 and RAC1 small GTPases. Its activation of these GTPases is crucial for neurite outgrowth, indicating its significant role in neural development.
Therapeutic significance:
Given its involvement in Adams-Oliver syndrome 2, a condition marked by congenital skin absence and limb defects, understanding the role of Dedicator of cytokinesis protein 6 could open doors to potential therapeutic strategies.